<DOC>
	<DOC>NCT02829827</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and tolerability, the pharmacokinetics and the efficacy of radiprodil in abolishing clinical spasms in subjects with drug-resistant infantile spasms</brief_summary>
	<brief_title>A Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)</brief_title>
	<detailed_description />
	<mesh_term>Spasm</mesh_term>
	<mesh_term>Muscle Cramp</mesh_term>
	<mesh_term>Spasms, Infantile</mesh_term>
	<criteria>Subject is male or female between 2 and 14 months of age Onset of spasms has occurred within 3 months of study start The diagnosis of infantile spasms (IS) Subject has drugresistant IS Subject has hematocrit greater than 60 Subject has any medical condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study Subject has a history or current condition predisposing to respiratory dysfunction Concomitant treatment with felbamate Ketogenic diet Previous treatment for IS other than StandardofCare (StoC) Clinically significant lab abnormalities Clinically significant abnormality on ECG that, in the opinion of the Investigator, increases the safety risks of participating in the study Subject has a lethal or potentially lethal condition other than IS, with a significant risk of death before 18 months of age Body weight is below 4 kg Known history of severe anaphylactic reaction secondary to medication intake or serious blood dyscrasias</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>14 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radiprodil</keyword>
	<keyword>Infantile spasms</keyword>
	<keyword>IS</keyword>
	<keyword>Infantile</keyword>
	<keyword>Spasms</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Paediatrics</keyword>
	<keyword>Drug-resistant</keyword>
	<keyword>West Syndrome</keyword>
	<keyword>Hypsarrhythmia</keyword>
</DOC>